Asciminib hydrochloride is described as a STAMP inhibitor, specifically targeting the ABL myristoyl pocket, Asciminib hydrochloride, marketed as Scemblix, are applied in research in Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) by binding to the allosteric site of wild-type ABL N-terminus, which is myristoylated, whereas the ABL fusion protein lacks this domain, enabling selective modulation of oncogenic signaling pathways and serving as a targeted therapeutic tool in hematologic cancer research.
Molecular Weight:
486.3
Purity:
99.91%
CAS Number:
[2119669-71-3]
Formula:
C20H19Cl2F2N5O3
Target:
Bcr-Abl
* VAT and and shipping costs not included. Errors and price changes excepted
